CAMP4 to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences:
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | |||
| Format: | Corporate Presentation | ||
| Date and Time: | February 12, 2025, 10:00 a.m. EST | ||
| Location: | Virtual | ||
| Webcast Link: | |||
| Leerink Partners Global Healthcare Conference | |||
| Format: | Fireside Chat | ||
| Date and Time: | March 10, 2025, 4:20 p.m. EST | ||
| Location: | Miami, Florida | ||
| Webcast Link: | |||
| Barclays 27th Annual Global Healthcare Conference | |||
| Format: | One-on-one meetings | ||
| Date and Time: | March 11-12, 2025 | ||
| Location: | Miami, Florida | ||
The presentation will be webcast live and can be accessed on the investor relations page of CAMP4’s website at A replay of the webcasts will be archived on the CAMP4 website for 30 days following the presentations.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of rare and prevalent genetic diseases where increasing healthy protein levels may offer meaningful therapeutic benefits. Our approach allows for targeted gene upregulation by harnessing a fundamental mechanism of how genes are controlled. To increase gene expression, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at and follow us on and .
Contacts
Investor Relations:
Sandya von der Weid
LifeSci Advisors
Media:
Jason Braco, Ph.D.
LifeSci Communications
